{"schema_version":"secwatch.filing_event.v1","accession":"0001613103-22-000006","form_type":"8-K","ticker":"MDT","cik":"0001613103","company_name":"Medtronic plc","filed_at":"2022-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.377598+00:00","generated_at":"2026-06-27T06:09:48.601166+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Medtronic Q3 FY2022 revenue flat at $7.8B; GAAP EPS $1.10 (+17%), non-GAAP EPS $1.37 (+6%)","bullets":["Revenue $7.763B flat YoY; organic growth 2%; COVID-19 impact on U.S. procedure volumes.","GAAP diluted EPS $1.10 (+17%); non-GAAP diluted EPS $1.37 (+6%), a penny above consensus.","Q4 guidance: organic revenue growth ~5.5%; non-GAAP EPS $1.56-$1.58.","Diabetes segment revenue down 7% as reported (-5% organic) driven by U.S. declines.","Cardiovascular up 3% organic; Medical Surgical up 1% organic; Neuroscience up 2% organic."],"urls":{"canonical":"https://secwatch.observer/filing/0001613103-22-000006","json":"https://secwatch.observer/filing/0001613103-22-000006.json","markdown":"https://secwatch.observer/filing/0001613103-22-000006.md","text":"https://secwatch.observer/filing/0001613103-22-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613103/000161310322000006/0001613103-22-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613103/000161310322000006/mdt-20220222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T06:09:48.601166+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}